Skip to main content

Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists’ questionnaire survey

Abstract

Background

Few good-quality clinical trials on adults with nephrotic syndrome exist. Thus, there are discrepancies between real-world practice and clinical practice guidelines. We conducted a questionnaire-based survey to investigate potential discrepancies and the factors associated with variations in clinical practice.

Methods

A questionnaire was administered electronically to all board-certified nephrologists in Japan. To examine clinical practice variations in relation to physician characteristics, we estimated the ratio of the mean duration of steroid therapy using a generalized linear model, and the odds ratio of higher level ordinal variables using an ordered logistic regression model.

Results

Responses of the 116 participants showed some variation for the majority of questions. Most participants (94.8%) indicated that screening for malignant tumors was “Conducted for almost all patients”. The duration of steroid therapy was found to be longer among physicians seeing ≥ 30 patients with nephrotic syndrome per month, both for minimal-change disease (ratio of mean 1.69; 95% CI 1.07–2.66) and membranous nephropathy (ratio of mean 1.71; 95% CI 1.09–2.69).

Conclusions

We identified practice patterns for nephrotic syndrome and discrepancies between clinical practice guidelines and actual practice. Defining the standard therapy for nephrotic syndrome may be necessary to generate high-quality evidence and develop clinical guidelines.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Japanese Society of Nephrology. JSN and MHLW Clinical Practice Guideline for Nephrotic Syndrome 2014. Nihon Jinzo Gakkai Shi. 2014;56:909–1028.

    Google Scholar 

  2. 2.

    Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167–73. https://doi.org/10.1038/ki.2008.24.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87:225–32. https://doi.org/10.1038/ki.2014.260.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Japanese Society of Nephrology. The number of kidney specialists by prefecture. IN: Renal Specialist. https://www.jsn.or.jp/specialist/listindex.php. Accessed 26 Aug 2018.

  5. 5.

    Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, et al. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study. Clin J Am Soc Nephrol CJASN. 2014;9:1040–8. https://doi.org/10.2215/CJN.12331213.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    OECD health statistics 2014—frequently requested data—OECD [Internet]. 2018. https://www.oecd.org/els/health-systems/oecd-health-statistics-2014-frequently-requested-data.htm. Accessed 26 Jan 2018.

  7. 7.

    Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397–404. https://doi.org/10.1093/jac/dkw157.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Cettomai D, Gelber AC, Christopher-Stine L. A survey of rheumatologists’ practice for prescribing pneumocystis prophylaxis. J Rheumatol. 2010;37:792–9. https://doi.org/10.3899/jrheum.090843.

    Article  PubMed  Google Scholar 

  9. 9.

    Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, et al. Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study. Clin Exp Nephrol. 2013;17:839–47. https://doi.org/10.1007/s10157-013-0793-9.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by a Grant-in-Aid for Intractable Renal Diseases Research, Research on rare and intractable diseases (eRad ID-17931232), and Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan. We are deeply grateful to all specialists who responded the questionnaire survey in this study.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Noriaki Kurita.

Ethics declarations

Conflict of interest

Honoraria: Hirokazu Okada (Kyowa Hakko Kirin, Daiichi Sankyo Inc., and Mitsubishi Tanabe Parma), Shoichi Maruyama (Kyowa Hakko Kirin Co., Ltd, Chugai pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.), and Yugo Shibagaki (Astellas Pharma, Teijin Pharma, Chugai Pharmaceuticals, Otsuka Pharmaceutical, Dainihon Sumitomo Pharmaceutical, and Daiichi-Sankyo). Research funding: Shoichi Maruyama (Sanwa Kagaku Kenkyusho Co., Ltd. and Rohto Pharmaceutical Co., Ltd.). Subsidies or Donations: Hirokazu Okada (Takeda Pharm., Chugai Pharm., Torii Pharm., Kyowa-Hakko Kirin, Pfizer, Boehringer Ingelheim, Astellas Pharm., Otsuka Pharm., MSD, Shionogi, Novartis, Sumitomo Dainippon Pharm., Mitsubishi Tanabe Pharm., and Daiichi Sankyo Co.), Yugo Shibagaki (Kyowa-Hakko Kirin, Sanwa Chemicals, Baxter, Takeda Pharmaceutical, Teijin Pharma, Tanabe Mitsubishi Pharma, and Pfizer), and Shoichi Maruyama (Asahi Kasei Pharma Co., Astellas Pharma Inc, Alexion Pharma Co., Otsuka Pharma Co., Kyowa Hakko Kirin Co., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai pharmac Co. Ltd., Teijin Pharma Ltd., Torii Pharmaceutical Co, Ltd., Baxter Ltd., Pfizer Japan Inc., Bristol-Myers Squibb., MSD K.K., and Mochida Pharma Co. Ltd.).

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted, and were approved by the Research Ethics Committee of Iwate Prefectural Central Hospital (approval number 1941) and conform to the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Participant consent was waived, as responses to the questionnaire were retrieved anonymously and no individual information of participants was retrieved.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

About this article

Verify currency and authenticity via CrossMark

Cite this article

Niihata, K., Nishiwaki, H., Kurita, N. et al. Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists’ questionnaire survey. Clin Exp Nephrol 23, 1288–1297 (2019). https://doi.org/10.1007/s10157-019-01772-z

Download citation

Keywords

  • Practice patterns
  • Guideline-practice gap
  • Nephrotic syndrome